EUVIMEDEUVIMED entdecken
Multizentrische StudieLeitlinieOpen Access · CC BY-NC 4.0

Guideline adherence in the management of aromatase inhibitor-induced bone loss in women with breast cancer

Pelin Menemencioğlu iD, Murat Kara, Hatice Gülgün Fırat, Ahmet Furkan Çolak iD, Yahya Demirler, Mahmud Fazıl Aksakal, Hasan Ocak, Hilmi Berkan Abacıoğlu, Berkay Yalçınkaya iD, Mustafa Toprak, Kübranur Demirel, Orhun Tunahan Cingöz und 7 weitere

Postgraduate Medical Journal · 2026

DOI: 10.1093/postmj/qgag098 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Postgraduate Medical Journal, 2026. Verfasst von Pelin Menemencioğlu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical and Rehabilitation Medicine, Hacettepe University Medical School, Altındağ, 06230 Ankara, Türkiye. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Bone Density Conservation Agents, Breast Neoplasms, Guideline Adherence. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Osteoporosis (OP) and aromatase inhibitor (AI)-induced bone loss are major concerns among postmenopausal women with breast cancer. This study aimed to comparatively evaluate guideline-concordant bone health management for OP and AI-induced bone loss across two tertiary centers.

Methods

We retrospectively analyzed medical records of 2224 postmenopausal women with breast cancer. Demographic characteristics, comorbidities, medication use, and baseline bone mineral density (BMD) and T-score values were extracted for all patients screened or followed between 2019 and 2024.

Results

Among 2224 women, AI use at the time of DXA assessment (N = 1146) was more frequent in Center 2 than Center 1 (79.4% vs. 35.6%, P < .001). Among AI users, OP prevalence was similar between centers (Center 1: 25.0%; Center 2: 26.2%); however, anti-osteoporotic treatment prescribing was higher in Center 2 (85.7% vs. 49.2%, P < .001). Among treatment-indicated non-osteoporotic AI users according to European Society of Medical Oncology guideline, prescribing rates were also higher in Center 2 (85.1% vs. 23.0%, P < .001). Among osteoporotic AI nonusers, treatment rates remained higher in Center 2 (75.9% vs. 45.8%, P < .001). Binary logistic regression confirmed center type as an independent predictor of treatment prescribing (OR: 9.414, 95% confidence interval: 6.669–13.289, P < .001).

Conclusion

Guideline-concordant prescribing for AI-induced bone loss differed substantially between the two centers. Prospective studies evaluating longitudinal BMD changes, fracture outcomes, and treatment persistence are warranted to determine the clinical impact of these differences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aromatase InhibitorsBone Density Conservation AgentsBreast NeoplasmsGuideline AdherenceOsteoporosisOsteoporosis, PostmenopausalAgedFemaleHumansMiddle AgedAbsorptiometry, PhotonBone DensityRetrospective Studies

Stichwörter der Autor:innen

ESMOanastrozolebisphosphonateletrozoleosteoporosis

Substanzen

Aromatase InhibitorsBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Physical and Rehabilitation Medicine, Hacettepe University Medical School, Altındağ, 06230 Ankara, Türkiye.
  • Department of Internal Medicine, Abdurrahman Yurtaslan Oncology Training and Research Hospital, Yenimahalle, 06200 Ankara, Türkiye.
  • Department of Pain Medicine, Hacettepe University Medical School, Altındağ, 06230 Ankara, Türkiye.
  • Division of Geriatrics, Abdurrahman Yurtaslan Oncology Training and Research Hospital, Yenimahalle, 06200 Ankara, Türkiye.
  • Division of Medical Oncology, Abdurrahman Yurtaslan Oncology Training and Research Hospital, Yenimahalle, 06200 Ankara, Türkiye.
  • Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Medical School, Altındağ, 06230 Ankara, Türkiye.

ORCID-Profile: Pelin Menemencioğlu, Ahmet Furkan Çolak, Berkay Yalçınkaya, Sercan Aksoy

Zitieren

APA

Menemencioğlu, P., Kara, M., Fırat, H. G., Çolak, A. F., Demirler, Y., Aksakal, M. F., Ocak, H., Abacıoğlu, H. B., Yalçınkaya, B., Toprak, M., Demirel, K., Cingöz, O. T., Sevinç, H., Kara, M. İ., Kara, Ö., Kaymak, B., Ateş, Ö., Aksoy, S., & Özçakar, L. (2026). Guideline adherence in the management of aromatase inhibitor-induced bone loss in women with breast cancer. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgag098

Vancouver

Menemencioğlu P, Kara M, Fırat HG, Çolak AF, Demirler Y, Aksakal MF, et al. Guideline adherence in the management of aromatase inhibitor-induced bone loss in women with breast cancer. Postgraduate Medical Journal. 2026. doi:10.1093/postmj/qgag098

BibTeX
@article{Menemenciolu2026,
  author = {Menemencioğlu, Pelin and Kara, Murat and Fırat, Hatice Gülgün and Çolak, Ahmet Furkan and Demirler, Yahya and Aksakal, Mahmud Fazıl and Ocak, Hasan and Abacıoğlu, Hilmi Berkan and Yalçınkaya, Berkay and Toprak, Mustafa and Demirel, Kübranur and Cingöz, Orhun Tunahan and Sevinç, Hazal and Kara, Melisa İrem and Kara, Özgür and Kaymak, Bayram and Ateş, Öztürk and Aksoy, Sercan and Özçakar, Levent},
  title = {Guideline adherence in the management of aromatase inhibitor-induced bone loss in women with breast cancer},
  journal = {Postgraduate Medical Journal},
  year = {2026},
  doi = {10.1093/postmj/qgag098}
}
Kostenlos starten →